Myxofibrosarcoma is a rare cancer affecting the connective tissues, most often appearing as a slow-growing lump in the arms or legs of older adults. Treatment decisions depend on the tumor’s location, size, grade, and whether the cancer has spread, with surgery serving as the foundation of care alongside radiation and chemotherapy in many cases.

How Doctors Approach Care for This Rare Cancer

When someone receives a diagnosis of myxofibrosarcoma, the main goal of treatment is to remove all cancer cells from the body and prevent the disease from returning. This cancer belongs to a group called soft tissue sarcomas, which are cancers that begin in the tissues connecting, supporting, and surrounding other body structures. Because myxofibrosarcoma can behave differently from person to person, doctors create individualized treatment plans based on several key factors.^[1]

The treatment strategy varies significantly depending on where the tumor is located, how large it has grown, and how fast its cells are dividing. Doctors also consider the patient’s overall health, age, and personal preferences. Some patients may need only surgery, while others benefit from a combination of surgery, radiation therapy, and chemotherapy. The disease stage—which describes how far the cancer has spread—plays a critical role in deciding which treatments to use and in what order.^[2]

One of the biggest challenges with myxofibrosarcoma is its tendency to grow into nearby healthy tissue in an irregular pattern, rather than forming a neat, defined lump. This infiltrative growth pattern makes it harder for surgeons to remove all cancer cells completely during an operation. As a result, this cancer has a higher chance of coming back after treatment compared to some other types of soft tissue sarcomas. For this reason, healthcare teams often recommend additional treatments beyond surgery to reduce the risk of recurrence.^[3]

Standard treatments approved by medical societies have been established based on years of clinical experience and research studies. At the same time, scientists continue to investigate new therapies through clinical trials. These research studies test innovative approaches that might improve outcomes for patients in the future. Some patients may have the opportunity to participate in these trials, which can provide access to cutting-edge treatments not yet widely available.^[11]

Surgery: The Foundation of Treatment

Surgery is the main treatment for myxofibrosarcoma that has not spread to other parts of the body. The surgeon’s goal is to remove the entire tumor along with a surrounding area of normal tissue. This border of healthy tissue, called a margin, helps ensure that no cancer cells are left behind. Because myxofibrosarcoma tends to send tiny extensions into surrounding tissue, achieving a clear margin is essential but can be challenging.^[6]

For tumors located in the arms or legs, surgeons perform what is called limb-sparing surgery. This approach aims to remove the cancer while preserving as much function of the limb as possible. In the past, amputation—removing part or all of a limb—was more common, but modern surgical techniques combined with radiation therapy have made it possible to save limbs in most cases. Amputation is now very rare and is considered only when the cancer has spread extensively or when it’s not possible to remove the tumor while maintaining limb function.^[12]

After surgery, a pathologist examines the removed tissue under a microscope to check the margins. If cancer cells are found at the edge of the removed tissue, it means the margins are positive, and some cancer may remain in the body. In this situation, doctors may recommend additional surgery to remove more tissue, or they may suggest radiation therapy to kill any remaining cancer cells. Achieving negative margins—where no cancer cells are seen at the edges—significantly reduces the chance of the cancer returning.^[10]

The recovery period after surgery depends on the size and location of the tumor and the extent of the operation. Patients may need physical therapy or occupational therapy to regain strength and function, especially if the surgery involved muscles or joints. Pain management and wound care are also important parts of the recovery process. Regular follow-up appointments allow doctors to monitor healing and watch for any signs that the cancer might be coming back.^[2]

Radiation Therapy: Targeting Hidden Cancer Cells

Radiation therapy uses powerful energy beams—usually X-rays or protons—to destroy cancer cells. For myxofibrosarcoma, radiation can be delivered before surgery, after surgery, or sometimes both, depending on the individual situation. The main purpose of radiation is to kill cancer cells that might be too small to see or remove during surgery, thereby reducing the chance of the tumor growing back.^[10]

When radiation is given before surgery, it is called neoadjuvant radiation. The goal is to shrink the tumor, which can make it easier for the surgeon to remove completely. Smaller tumors may require less extensive surgery, potentially preserving more healthy tissue and function. However, neoadjuvant radiation can delay surgery while the treatment course is completed, typically over several weeks.^[12]

More commonly, radiation is given after surgery, known as adjuvant radiation. This approach targets the area where the tumor was located to eliminate any microscopic cancer cells that might remain. Adjuvant radiation is particularly important when the surgical margins are close or positive, meaning cancer cells were found near or at the edge of the removed tissue. Studies have shown that adding radiation after surgery significantly reduces the risk of local recurrence in high-grade tumors.^[11]

The radiation treatment itself is painless and usually involves short daily sessions over several weeks. During each session, the patient lies still while a machine directs radiation beams at the treatment area. Side effects can include fatigue, skin irritation in the treated area (similar to sunburn), and temporary swelling. Most side effects improve after treatment ends, though some patients may experience long-term effects such as skin changes, stiffness, or swelling in the treated limb. The radiation oncology team monitors patients closely throughout treatment and provides strategies to manage side effects.^[6]

Chemotherapy: Medication-Based Treatment

Chemotherapy refers to drugs that kill rapidly dividing cancer cells throughout the body. Unlike surgery and radiation, which treat cancer in a specific location, chemotherapy travels through the bloodstream and can reach cancer cells wherever they may be. For myxofibrosarcoma, chemotherapy is not always needed, but it may be recommended in certain situations.^[12]

Chemotherapy might be considered for patients with high-grade myxofibrosarcoma that is large or growing quickly, as these tumors have a higher risk of spreading to distant parts of the body, especially the lungs. It may also be used when the cancer has already spread (metastatic disease) or when it comes back after initial treatment. The most commonly used chemotherapy drug for soft tissue sarcomas, including myxofibrosarcoma, is doxorubicin, often combined with other agents.^[8]

The effectiveness of chemotherapy for myxofibrosarcoma specifically is not entirely clear. Some types of chemotherapy have shown better results than others in studies, but overall, the benefit appears to be modest compared to other soft tissue sarcomas. Because of this uncertainty and the significant side effects chemotherapy can cause, doctors carefully weigh the potential benefits against the risks for each individual patient.^[6]

Chemotherapy side effects vary depending on which drugs are used but commonly include nausea, vomiting, hair loss, fatigue, and increased risk of infection due to low blood cell counts. Some chemotherapy drugs can affect the heart, kidneys, or other organs, so patients receiving these treatments need regular monitoring. Supportive care medications can help manage many of these side effects and improve quality of life during treatment.^[11]

Grading and Staging: Understanding Your Cancer’s Behavior

Myxofibrosarcoma is classified into three grades—low, intermediate, and high—based on how the cancer cells look under a microscope. The grade reflects how abnormal the cells appear and how quickly they are dividing. Low-grade tumors have cells that look more like normal cells and tend to grow slowly. High-grade tumors have very abnormal cells that divide rapidly and are more likely to spread to other parts of the body. The grade of the tumor is one of the most important factors in determining the appropriate treatment and predicting outcomes.^[3]

In addition to grading, doctors use a staging system to describe how far the cancer has spread. Staging takes into account the tumor’s size, its grade, how deeply it has grown into surrounding tissues, and whether it has spread to lymph nodes or distant organs. For myxofibrosarcoma, the lungs are the most common site of distant spread. Staging helps doctors predict prognosis and plan treatment. Early-stage, low-grade tumors generally have a better outlook than advanced, high-grade tumors.^[9]

To determine the stage, doctors use imaging tests such as CT scans or MRI to see the tumor’s size and location and to check for spread to other areas. A biopsy—where a small sample of the tumor is removed and examined in a laboratory—confirms the diagnosis and provides information about the grade. Sometimes additional imaging, like a CT scan of the chest, is done to look for lung metastases. All this information is brought together to assign a stage and guide treatment decisions.^[4]

Innovative Approaches Being Studied in Clinical Trials

While surgery, radiation, and chemotherapy remain the standard treatments for myxofibrosarcoma, researchers are actively investigating new therapies that might improve outcomes, especially for patients with advanced or recurrent disease. These experimental treatments are tested in clinical trials—carefully controlled research studies that evaluate new approaches to prevention, detection, or treatment of cancer.^[11]

One area of active research involves targeted therapies, which are drugs designed to attack specific features of cancer cells. Unlike traditional chemotherapy, which affects all rapidly dividing cells in the body, targeted therapies aim to interfere with specific molecules involved in cancer growth and spread. Scientists are studying various molecular pathways in myxofibrosarcoma to identify potential targets for new drugs. These therapies might work by blocking signals that tell cancer cells to multiply, cutting off their blood supply, or interfering with DNA repair mechanisms.^[12]

Immunotherapy is another promising approach being explored in clinical trials. These treatments work by helping the patient’s own immune system recognize and attack cancer cells. Some immunotherapy drugs, such as checkpoint inhibitors, remove the “brakes” that prevent immune cells from attacking tumors. While immunotherapy has shown remarkable success in certain types of cancer, its role in treating myxofibrosarcoma is still being investigated. Early studies are examining whether these treatments might benefit patients whose cancer has spread or returned after standard therapy.^[12]

Clinical trials typically progress through three phases. Phase I trials focus primarily on safety, determining the appropriate dose of a new treatment and identifying side effects in a small group of patients. Phase II trials evaluate whether the treatment shows signs of effectiveness against the cancer while continuing to monitor safety. Phase III trials compare the new treatment directly with current standard treatments in a larger group of patients to determine whether it offers better outcomes. Only treatments that successfully complete all phases and demonstrate both safety and effectiveness become approved for general use.^[11]

Participation in clinical trials may be an option for patients with myxofibrosarcoma, particularly those with advanced disease or cancer that has not responded to standard treatments. Trials may be available at specialized cancer centers in various locations, including the United States, Europe, and other regions. Eligibility criteria vary by study and typically include factors such as the stage and grade of the cancer, previous treatments received, and overall health status. Patients interested in clinical trials can discuss this option with their healthcare team or search clinical trial databases to identify relevant studies.^[3]

Monitoring and Managing Recurrence

Even after successful initial treatment, myxofibrosarcoma has a tendency to return, a situation called recurrence. The cancer may come back in the same location where it originally appeared (local recurrence) or in distant parts of the body (distant recurrence or metastasis). Because of this risk, regular follow-up care is a critical part of the treatment journey.^[2]

Follow-up typically involves regular physical examinations and imaging scans to check for signs of cancer returning. The frequency of these appointments is usually more frequent in the first few years after treatment, when recurrence risk is highest, and may become less frequent over time. If the cancer does return, treatment options depend on where it recurs and what treatments were used initially. Local recurrences may be treated with additional surgery, sometimes combined with radiation if it wasn’t used before. Distant recurrences usually require systemic therapy such as chemotherapy or, potentially, experimental treatments available through clinical trials.^[9]

Studies have shown that local recurrence occurs in a significant percentage of patients, with some reports indicating rates of around 20-25% even after adequate surgery and radiation. The average time until recurrence is about 19 months, though it can happen sooner or later. When myxofibrosarcoma returns, it sometimes becomes more aggressive, with a higher grade than the original tumor. This underscores the importance of vigilant monitoring and prompt evaluation of any new lumps or symptoms.^[19]

Most Common Treatment Methods

• Surgery
  • Wide surgical resection to remove the tumor along with surrounding healthy tissue margins
  • Limb-sparing surgery for tumors in arms or legs to preserve function
  • Additional surgery if initial margins are positive
• Radiation Therapy
  • Neoadjuvant radiation given before surgery to shrink tumors
  • Adjuvant radiation delivered after surgery to eliminate remaining cancer cells
  • Particularly important when surgical margins are close or positive
• Chemotherapy
  • Doxorubicin-based regimens for high-grade tumors or metastatic disease
  • Used when cancer has spread or there is high risk of recurrence
  • Effectiveness varies, with benefits being modest compared to other sarcomas
• Targeted Therapies (Experimental)
  • Drugs designed to interfere with specific molecular pathways in cancer cells
  • Being studied in clinical trials for advanced or recurrent disease
  • Aim to block signals involved in cancer cell growth and spread
• Immunotherapy (Experimental)
  • Checkpoint inhibitors that help the immune system recognize cancer cells
  • Under investigation in clinical trials
  • May be an option for patients with metastatic or treatment-resistant disease